| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Marios Politis | Q64856266 |
| Flavia Niccolini | Q90879542 | ||
| Gennaro Pagano | Q38321619 | ||
| P2860 | cites work | Striatal D1 and D2 receptor binding in patients with Huntington's disease and other choreas A PET study | Q45307413 |
| Distinct roles of PDE4 and PDE10A in the regulation of cAMP/PKA signaling in the striatum | Q23909635 | ||
| A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. | Q27860836 | ||
| Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease | Q28302222 | ||
| The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington's disease | Q28705237 | ||
| Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease | Q28748849 | ||
| Huntington disease: natural history, biomarkers and prospects for therapeutics | Q30774172 | ||
| Neuroimaging in Huntington's disease | Q30834004 | ||
| Neuroimaging in Parkinson disease: from research setting to clinical practice | Q30868628 | ||
| Recent imaging advances in neurology. | Q30916063 | ||
| Unilateral transplantation of human primary fetal tissue in four patients with Huntington's disease: NEST-UK safety report ISRCTN no 36485475. | Q31118947 | ||
| Differential excitability and modulation of striatal medium spiny neuron dendrites | Q33382961 | ||
| Differential loss of striatal projection neurons in Huntington disease | Q33637273 | ||
| Disorders of the basal ganglia and their modern management. | Q33725428 | ||
| Optimizing functional imaging protocols for assessing the outcome of fetal cell transplantation in Parkinson's disease | Q33898436 | ||
| Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. | Q34602111 | ||
| CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches | Q34624785 | ||
| Thalamic metabolism and symptom onset in preclinical Huntington's disease | Q34692568 | ||
| Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington's disease pathology | Q35134776 | ||
| Microglial functions and proteases | Q35141400 | ||
| Central motor processing in Huntington's disease. A PET study | Q45295098 | ||
| Cortical control of movement in Huntington's disease. A PET activation study | Q45295104 | ||
| Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes | Q45295568 | ||
| [11C]raclopride-PET studies of the Huntington's disease rate of progression: relevance of the trinucleotide repeat length | Q45295668 | ||
| The relationship between striatal dopamine receptor binding and cognitive performance in Huntington's disease | Q45296236 | ||
| PET imaging shows loss of striatal PDE10A in patients with Huntington disease | Q45296605 | ||
| Positron emission tomography in the early diagnosis of Huntington's disease | Q45297664 | ||
| Regional and subtype selective changes of neurotransmitter receptor density in a rat transgenic for the Huntington's disease mutation | Q45297722 | ||
| Cross sectional PET study of cerebral adenosine A₁ receptors in premanifest and manifest Huntington's disease | Q45297840 | ||
| Positron emission tomography after fetal transplantation in Huntington's disease | Q45297853 | ||
| PET scan investigations of Huntington's disease: cerebral metabolic correlates of neurological features and functional decline | Q45297931 | ||
| Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease | Q45298088 | ||
| Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington disease. | Q45298570 | ||
| Positron emission tomographic scan investigations of Huntington's disease: cerebral metabolic correlates of cognitive function | Q45299001 | ||
| Brain energy metabolism and dopaminergic function in Huntington's disease measured in vivo using positron emission tomography | Q45299145 | ||
| Widespread decrease of type 1 cannabinoid receptor availability in Huntington disease in vivo | Q45299326 | ||
| Neurotransmitter receptor alterations in Huntington's disease: autoradiographic and homogenate studies with special reference to benzodiazepine receptor complexes | Q45299456 | ||
| Extrastriatal dopamine D(2) receptor binding in Huntington's disease | Q45299934 | ||
| Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease. | Q45299986 | ||
| Early decrease of type 1 cannabinoid receptor binding and phosphodiesterase 10A activity in vivo in R6/2 Huntington mice | Q45300196 | ||
| Decreased striatal monoaminergic terminals in Huntington disease | Q45300337 | ||
| Benzodiazepine receptor binding in Huntington's disease: [11C]flumazenil uptake measured using positron emission tomography | Q45300345 | ||
| The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease | Q45300428 | ||
| Diagnostic criteria for Huntington's disease based on natural history | Q45301388 | ||
| Microglial activation correlates with severity in Huntington disease: a clinical and PET study. | Q45301519 | ||
| Motor and cognitive improvements in patients with Huntington's disease after neural transplantation | Q45301920 | ||
| The phosphodiesterase 10 positron emission tomography tracer, [18F]MNI-659, as a novel biomarker for early Huntington disease | Q45302323 | ||
| Regional cerebral glucose metabolism after pridopidine (ACR16) treatment in patients with Huntington disease | Q45302933 | ||
| Huntington's disease: effect of memantine on FDG-PET brain metabolism? | Q45303289 | ||
| Microglial activation in presymptomatic Huntington's disease gene carriers | Q45304723 | ||
| Regional and progressive thinning of the cortical ribbon in Huntington's disease | Q45305508 | ||
| The dynamics of cortical and hippocampal atrophy in Alzheimer disease | Q35643088 | ||
| Decreased Metabolism in the Cerebral Cortex in Early-Stage Huntington's Disease: A Possible Biomarker of Disease Progression? | Q36528726 | ||
| Radiosynthesis and in vivo evaluation of two imidazopyridineacetamides, [(11)C]CB184 and [ (11)C]CB190, as a PET tracer for 18 kDa translocator protein: direct comparison with [ (11)C](R)-PK11195. | Q36809409 | ||
| Metabolic network as a progression biomarker of premanifest Huntington's disease | Q37123932 | ||
| Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity | Q37132239 | ||
| Brain imaging after neural transplantation | Q37796021 | ||
| Brain networks in Huntington disease | Q37834193 | ||
| Positron emission tomography neuroimaging in Parkinson's disease | Q37929598 | ||
| Positron emission tomography imaging in neurological disorders | Q37980609 | ||
| Integrating neurotransmission in striatal medium spiny neurons. | Q37986667 | ||
| Imaging of microglia in patients with neurodegenerative disorders | Q38015834 | ||
| The incidence and prevalence of Huntington's disease: a systematic review and meta-analysis | Q38018281 | ||
| Integrative neurobiology of metabolic diseases, neuroinflammation, and neurodegeneration. | Q38515285 | ||
| The Neuropathology of Huntington´s disease: classical findings, recent developments and correlation to functional neuroanatomy | Q38696568 | ||
| Alterations in the benzodiazepine receptor of Huntington's diseased human brain | Q39242585 | ||
| Cerebral glucose and dopa metabolism in movement disorders. | Q39483640 | ||
| The GABA Neurons and their axon terminals in rat corpus striatum as demonstrated by GAD immunocytochemistry | Q40260170 | ||
| Localization of functional activity in the central nervous system by measurement of glucose utilization with radioactive deoxyglucose | Q40324066 | ||
| Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington's disease gene carriers | Q40617788 | ||
| Huntington's disease progression. PET and clinical observations. | Q40787958 | ||
| Modulation of neurotransmission by cannabinoids in the basal ganglia | Q41371378 | ||
| Identifying improved TSPO PET imaging probes through biomathematics: the impact of multiple TSPO binding sites in vivo | Q41823077 | ||
| Adenosine and glutamate extracellular concentrations and mitogen-activated protein kinases in the striatum of Huntington transgenic mice. Selective antagonism of adenosine A2A receptors reduces transmitter outflow | Q42467111 | ||
| Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage | Q42512972 | ||
| Cortical dopamine dysfunction in symptomatic and premanifest Huntington's disease gene carriers | Q43255746 | ||
| Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study | Q43469689 | ||
| Metabolic network abnormalities in early Huntington's disease: an [(18)F]FDG PET study. | Q43790732 | ||
| Opioid peptides in Huntington's disease: alterations in prodynorphin and proenkephalin system | Q44344438 | ||
| Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study. | Q44400030 | ||
| Striatal neural grafting improves cortical metabolism in Huntington's disease patients | Q44649029 | ||
| Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington's disease transgenic mice prior to the onset of motor symptoms | Q44748091 | ||
| 18F-FDG PET uptake in the pre-Huntington disease caudate affects the time-to-onset independently of CAG expansion size | Q45288484 | ||
| Altered PDE10A expression detectable early before symptomatic onset in Huntington's disease | Q45289206 | ||
| Dopamine D1 receptor number--a sensitive PET marker for early brain degeneration in Huntington's disease | Q45290030 | ||
| Positron emission tomography measures of benzodiazepine receptors in Huntington's disease | Q45290810 | ||
| Hypothalamic involvement in Huntington's disease: an in vivo PET study | Q45291041 | ||
| Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington's disease | Q45291252 | ||
| Riluzole protects Huntington disease patients from brain glucose hypometabolism and grey matter volume loss and increases production of neurotrophins. | Q45293052 | ||
| Functional brain changes in presymptomatic Huntington's disease | Q45293738 | ||
| PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease | Q45294163 | ||
| A PET study of word generation in Huntington's disease: effects of lexical competition and verb/noun category | Q45294571 | ||
| Cortical and subcortical glucose consumption measured by PET in patients with Huntington's disease. | Q45294680 | ||
| 11C-diprenorphine binding in Huntington's disease: a comparison of region of interest analysis with statistical parametric mapping | Q45295068 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Huntington's disease | Q190564 |
| positron emission tomography | Q208376 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 1171-82 | |
| P577 | publication date | 2016-06-01 | |
| P1433 | published in | European Journal of Nuclear Medicine and Molecular Imaging | Q15708890 |
| P1476 | title | Current status of PET imaging in Huntington's disease | |
| P478 | volume | 43 |
| Q28075227 | A systematic review of lessons learned from PET molecular imaging research in atypical parkinsonism |
| Q49719233 | Alteration of GABAergic neurotransmission in Huntington's disease. |
| Q45303467 | Altered behavioral responses to gamma-aminobutyric acid pharmacological agents in a mouse model of Huntington's disease. |
| Q92852974 | Cerebral Vitamin B5 (D-Pantothenic Acid) Deficiency as a Potential Cause of Metabolic Perturbation and Neurodegeneration in Huntington's Disease |
| Q41566638 | Chronic exposure to dopamine agonists affects the integrity of striatal D2 receptors in Parkinson's patients |
| Q34547558 | Current Pharmacological Approaches to Reduce Chorea in Huntington's Disease |
| Q48044131 | Expanded neurochemical profile in the early stage of Huntington disease using proton magnetic resonance spectroscopy |
| Q39165036 | Huntington Disease: Linking Pathogenesis to the Development of Experimental Therapeutics |
| Q92923586 | Huntington's Disease: A Review of the Known PET Imaging Biomarkers and Targeting Radiotracers |
| Q29248766 | Molecular Imaging Markers to Track Huntington’s Disease Pathology |
| Q89338605 | Multiple clinical features of Huntington's disease correlate with mutant HTT gene CAG repeat lengths and neurodegeneration |
| Q57493665 | Neuroimaging of Sleep Disturbances in Movement Disorders |
| Q57021540 | Novel Imaging Biomarkers for Huntington's Disease and Other Hereditary Choreas |
| Q42369736 | PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson's Disease |
| Q33831774 | Striatal Vulnerability in Huntington's Disease: Neuroprotection Versus Neurotoxicity |
| Q45295893 | Striatal hypometabolism in premanifest and manifest Huntington's disease patients |
| Q48272772 | TAK-063, a novel PDE10A inhibitor with balanced activation of direct and indirect pathways, provides a unique opportunity for the treatment of schizophrenia |
| Q88960978 | TSPO-PET imaging using [18F]PBR06 is a potential translatable biomarker for treatment response in Huntington's disease: preclinical evidence with the p75NTR ligand LM11A-31 |
| Q28072937 | The chicken or the egg: mitochondrial dysfunction as a cause or consequence of toxicity in Huntington's disease |
| Q48372783 | The serotonergic system in Parkinson's patients with dyskinesia: evidence from imaging studies |
Search more.